Baader Bank Aktiengesellschaft Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Baader Bank Aktiengesellschaft trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 32.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,846 shares of the biopharmaceutical company's stock after selling 1,807 shares during the period. Baader Bank Aktiengesellschaft's holdings in Alnylam Pharmaceuticals were worth $905,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ALNY. Huntington National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. Washington Trust Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 153 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insider Activity

In related news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock valued at $20,622,925 in the last 90 days. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ALNY. Piper Sandler reiterated an "overweight" rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Raymond James increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. TD Cowen raised their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. HC Wainwright reissued a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Up 1.7 %

Alnylam Pharmaceuticals stock traded up $4.75 during trading on Thursday, hitting $278.74. 243,910 shares of the company were exchanged, compared to its average volume of 672,415. The business's 50 day moving average is $249.42 and its 200 day moving average is $260.65. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a market capitalization of $35.95 billion, a P/E ratio of -106.20 and a beta of 0.34. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The company's quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.15 EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.